AstraZeneca (AZN) Scheduled to Post Earnings on Thursday

Share on StockTwits

AstraZeneca (NYSE:AZN) is set to post its quarterly earnings results before the market opens on Thursday, October 24th. Analysts expect AstraZeneca to post earnings of $0.45 per share for the quarter. AstraZeneca has set its FY19 guidance at $3.50-3.70 EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

AstraZeneca (NYSE:AZN) last released its quarterly earnings data on Thursday, July 25th. The company reported $0.73 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.43. AstraZeneca had a net margin of 9.38% and a return on equity of 35.83%. The firm had revenue of $5.72 billion for the quarter, compared to the consensus estimate of $5.57 billion. During the same period in the previous year, the company earned $0.69 earnings per share. The company’s quarterly revenue was up 10.9% on a year-over-year basis. On average, analysts expect AstraZeneca to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

AZN stock opened at $43.92 on Wednesday. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.75 and a current ratio of 0.95. The company’s 50-day simple moving average is $44.07 and its 200 day simple moving average is $41.56. AstraZeneca has a 52 week low of $35.30 and a 52 week high of $46.22. The company has a market capitalization of $116.32 billion, a PE ratio of 25.39, a price-to-earnings-growth ratio of 1.48 and a beta of 0.47.

In other news, major shareholder Plc Astrazeneca acquired 425,000 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was acquired at an average price of $19.00 per share, with a total value of $8,075,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Several equities analysts recently commented on AZN shares. HSBC restated a “sell” rating on shares of AstraZeneca in a research note on Thursday, October 17th. Argus upped their price target on shares of AstraZeneca to $50.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. DZ Bank downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Tuesday, September 3rd. Zacks Investment Research downgraded shares of AstraZeneca from a “strong-buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research note on Thursday, October 3rd. Finally, ValuEngine downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Four equities research analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $46.53.

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Recommended Story: Moving Average Convergence Divergence (MACD)

Earnings History for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

HashNet BitEco  Price Hits $0.0182 on Exchanges
HashNet BitEco Price Hits $0.0182 on Exchanges
Lition Reaches Market Capitalization of $1.10 Million
Lition Reaches Market Capitalization of $1.10 Million
Jason Philip Dinapoli Purchases 5,000 Shares of Heritage Commerce Corp.  Stock
Jason Philip Dinapoli Purchases 5,000 Shares of Heritage Commerce Corp. Stock
Short Interest in Superconductor Technologies, Inc.  Rises By 173.0%
Short Interest in Superconductor Technologies, Inc. Rises By 173.0%
IF Bancorp Inc  Short Interest Up 309.1% in October
IF Bancorp Inc Short Interest Up 309.1% in October
Cardlytics  Sees Strong Trading Volume After Analyst Upgrade
Cardlytics Sees Strong Trading Volume After Analyst Upgrade


© 2006-2019 Ticker Report